首页>
外国专利>
PERSONALIZED THERAPY OF INFLAMMATION-ASSOCIATED CANCER USING METHODS OF ASSESSING THE SUSCEPTIBILITY OF A SUBJECT TO THE TREATMENT WITH EGFR INHIBITORS/ANTAGONISTS
PERSONALIZED THERAPY OF INFLAMMATION-ASSOCIATED CANCER USING METHODS OF ASSESSING THE SUSCEPTIBILITY OF A SUBJECT TO THE TREATMENT WITH EGFR INHIBITORS/ANTAGONISTS
展开▼
机译:使用评估EGFR抑制剂/拮抗剂治疗受试者敏感性的方法对发炎相关的癌症进行个体化治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist. The invention also relates to EGFR inhibitors/antagonists for use in the treatment or amelioration of inflammation-associated cancer. The invention furthermore provides in vitro methods of prognosing the survival time, progression-free survival time or disease course of a subject that has been diagnosed or suspected of suffering from from inflammation-associated cancer. In addition thereto, the invention relates to in vitro diagnostic methods of assessing the proneness of a subject to develop inflammation-associated cancer in which the expression of EGFR is determined in myeloid cells from the subject.
展开▼